Does the law require reinterpretation and return of revised genomic results?

[1]  W. Chung,et al.  Correction to: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[2]  H. S. Brown,et al.  Genetic Variant Reinterpretation: Economic and Population Health Management Challenges. , 2020, Population health management.

[3]  G. Marchant,et al.  From Genetics to Genomics: Facing the Liability Implications in Clinical Care , 2020, Journal of Law, Medicine & Ethics.

[4]  W. Chung,et al.  Can Clinical Genetics Laboratories be Sued for Medical Malpractice? , 2020, Annals of health law and life sciences.

[5]  W. Chung,et al.  Is there a duty to reinterpret genetic data? The ethical dimensions , 2019, Genetics in Medicine.

[6]  A. McGuire,et al.  Who’s on third? Regulation of third-party genetic interpretation services , 2019, Genetics in Medicine.

[7]  Stephanie M Fullerton,et al.  Third-Party Genetic Interpretation Tools: A Mixed-Methods Study of Consumer Motivation and Behavior. , 2019, American journal of human genetics.

[8]  Ellen Wright Clayton,et al.  Improving recommendations for genomic medicine: building an evolutionary process from clinical practice advisory documents to guidelines , 2019, Genetics in Medicine.

[9]  Joshua L. Deignan,et al.  Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG) , 2019, Genetics in Medicine.

[10]  B. Knoppers,et al.  Letter: Relearning the 3 R’s? Reinterpretation, recontact, and return of genetic variants , 2019, Genetics in Medicine.

[11]  The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG) , 2019, Genetics in Medicine.

[12]  Joshua L. Deignan,et al.  Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[13]  E. Shortliffe,et al.  Clinical Decision Support in the Era of Artificial Intelligence. , 2018, JAMA.

[14]  N. Hawkins,et al.  Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics , 2018, European Journal of Human Genetics.

[15]  T. M. Morgan.  Genomic Screening: The Mutation and the Mustard Seed , 2018, Journal of Law, Medicine & Ethics.

[16]  B. Wilfond,et al.  Pediatric clinical exome/genome sequencing and the engagement process: encouraging active conversation with the older child and adolescent: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[17]  Patrick Reineke,et al.  False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care , 2018, Genetics in Medicine.

[18]  Caitlin Chisholm,et al.  Reinterpretation of sequence variants: one diagnostic laboratory’s experience, and the need for standard guidelines , 2017, Genetics in Medicine.

[19]  Stephanie M. Fullerton,et al.  “Bridge to the Literature”? Third-Party Genetic Interpretation Tools and the Views of Tool Developers , 2018, Journal of Genetic Counseling.

[20]  B. Evans.  HIPAA's Individual Right of Access to Genomic Data: Reconciling Safety and Civil Rights. , 2018, American journal of human genetics.

[21]  Murthy V. Devarakonda,et al.  Automated problem list generation and physicians perspective from a pilot study , 2017, Int. J. Medical Informatics.

[22]  G. Marchant,et al.  Physicians' duty to recontact and update genetic advice. , 2017, Personalized medicine.

[23]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[24]  Lisa Kalman,et al.  Assuring the Quality of Next-Generation Sequencing in Clinical Microbiology and Public Health Laboratories , 2016, Journal of Clinical Microbiology.

[25]  A. StAteMent.  ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing , 2014, Genetics in Medicine.

[26]  A. StAteMent.  Scope of practice: a statement of the American College of Medical Genetics and Genomics (ACMG) , 2015, Genetics in Medicine.

[27]  M. Dorschner,et al.  Regulatory changes raise troubling questions for genomic testing , 2014, Genetics in Medicine.

[28]  Patricia A. Deverka,et al.  Clinical Integration of Next Generation Sequencing: Coverage and Reimbursement Challenges , 2014, Journal of Law, Medicine & Ethics.

[29]  B. Evans.  Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[30]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[31]  M. Rothstein,et al.  Health Information Technology and Physicians’ Duty to Notify Patients of New Medical Developments , 2012 .

[32]  Brian H Shirts,et al.  Changing interpretations, stable genes: responsibilities of patients, professionals, and policy makers in the clinical interpretation of complex genetic information , 2008, Genetics in Medicine.

[33]  M. Mello,et al.  Of Swords and Shields: The Role of Clinical Practice Guidelines in Medical Malpractice Litigation , 2001 .